II. Indications
- Analgesia in rheumatic conditions (other agents including NSAIDs are preferred)
- Prevention of coronary and cerebrovascular events
- See Cardiac Risk Management
- Mainstay of secondary and tertiary prevention
- Has fallen out of favor for primary cardiovascular disease prevention aside from high risk patients age 40 to 60 years
- See decision aid in resources below
III. Contraindications
- Children with viral illness (Varicella, Influenza)
- Risk of Reye's Syndrome (FDA Black Box Warning)
- Gout
- Hypersensitivity to Aspirin
- Active Peptic Ulcer Disease
IV. History
- Willow bark contains Salicin (Salicylic acid)
- Used in folk medicine for mild pain and fever
- Acetylsalicylic acid is a derivative of salicylic acid
- Synthesized in 1853 by the Bayer brothers
V. Mechanism: NSAID related effects
- Antiinflammatory effect
- Inhibits Prostaglandin biosynthesis
-
Analgesic effect
- Relieves pain of mild to moderate intensity
- Antipyretic (Lowers Temperature)
VI. Mechanism: Platelet Effects
- Inhibits Thromboxane synthesis
- Inhibits Platelet aggregation
- Aspirin poisons the Platelets for its remaining life (using an example patient with 250,000 Platelet Count)
- New Platelets are generated at a rate of 10% per day (25,000/day for a patient with a 250,000 Platelet Count)
- By 2 days off Aspirin, a patient will have 50,000 normal Platelets (enough to counter bleeding)
- By 7 days off Aspirin, a patient will have 70% or 175,000 normal Platelets (typical level required for elective surgery)
- By 10 days off Aspirin, a patient will have 100%normal Platelets (level required by some clinicians for major surgery)
VII. Dosing
- Use lowest appropriate dose (reduces adverse effects)
- Anti-Platelet action
- General
- Do not exceed 81 to 160 mg daily if on Coumadin
- Coronary Artery Disease
- Immediate Myocardial Infarction Management: 325 mg
- Primary coronary disease prevention: 81 mg orally daily
- As of 2018, Aspirin is no longer recommended for primary prevention in most patients
- Tertiary prevention (post-MI)
- Aspirin 81 mg orally daily
- Similar efficacy in coronary disease prevention as the 325 mg dose
- Half the risk of gastrointestinal Hemorrhage as the 325 mg dose
- References
- Aspirin 81 mg orally daily
- Cerebrovascular Accident
- Prevention in known vascular disease: 160-325 mg daily
- OConnor (2001) Am J Cardiol 88:541-6 [PubMed]
- General
- Antipyretic or Analgesic Dose
- Adult: 600 mg PO q4 hours
- Adult: 650-1000 mg PO q4-6 hours
- Antiinflammatory dose
- Adult: 4 grams maximum per day
VIII. Preparations: Extended Release Aspirin
- Durlaza ( Extended-release Aspirin)
- No evidence that extended release Aspirin ($6/pill) has advantages over Aspirin 81 mg ($0.01/pill)
- (2015) Presc Lett 22(12): 71
- Vazalore (liquid-filled Aspirin capsule)
- Designed for delayed absorption to Small Intestine, postulated to reduce Gastrointestinal Bleeding
- No evidence that Vazalore reduces longterm Gastrointestinal Bleeding risk
- Expensive ($1 per capsule, compaired with $0.01/pill of standard Aspirin)
- (2021) Presc Lett 28(11): 62
IX. Drug Interactions
- Ibuprofen inactivates Aspirin Anticoagulation effect
X. Effects
XI. Advantages
- Safer and lower cost than many NSAIDs
- Aspirin is an underused medication
- Coronary disease prevention
- Falling out of favor in the primary prevention of lower risk patients without Myocardial Infarction or stroke
- Number Needed to Treat: 1 in 250 to prevent one first cardiovascular event (primary prevention)
- Aspirin is still an important mainstay of secondary prevention (known cardiovascular disease)
- Aspirin is still considered beneficial for primary prevention when 10 year CVD risk >10% in age 40 to 60 years
- Aspirin risk may outweigh benefit over age 75 years (consider discontinuing Aspirin in advanced age)
- Benefits may not outweigh the risks of GI Bleeding, Hemorrhagic CVA
- Number Needed to Harm: 1 in 200 to result in major bleeding
- Hemorrhage risk increases with older age, male gender, Tobacco Abuse, NSAID and Anticoagulant use
- References
- Falling out of favor in the primary prevention of lower risk patients without Myocardial Infarction or stroke
- Other benefits
- May reduce Colorectal Cancer risk (NNT 77)
XII. Adverse Effects
- Gastrointestinal Effects
- Gastrointestinal intolerance
- Peptic Ulcer Disease (Erosive Gastritis)
- Aspirin higher risk for Peptic Ulcer Disease
- Other Salicylates have lower risk than most NSAIDs
- Gastrointestinal Bleeding
- Middle aged: 2-4 per 1000 on Aspirin 5 years
- Older patient: 4-12 per 1000 on Aspirin for 5 years
- Roderick (1993) Br J Clin Pharmacol 35:219-26 [PubMed]
- Central Nervous System Effects: Salicylism
- Central Respiratory effects
- Very high dose: Hyperpnea
- Lethal doses: Respiratory depression or apnea
- Miscellaneous Effects
- Serum Uric Acid changes
- Asymptomatic hepatitis
- Exacerbation of Renal Insufficiency
- Hypersensitivity Reaction (Aspirin Allergy)
- Associated with Nasal Polyps and Asthma
XIII. Management: Reversal
- Platelet Transfusion 1 unit (6 pack)
- Consider Desmopressin (DDAVP) 0.3 mcg/kg (expert opinion)
- Consider Recombinant activated Clotting Factor VII (rFVIIa) 30-90 mcg/kg (expert opinion)
XIV. Resources
- Aspirin Guide
- http://www.aspiringuide.com/
- Web-based Shared Decision Making tool for primary prevention use
XV. References
- McCarty (1972) Arthritis and Allied Conditions
- Katzung (1989) Basic and Clinical Pharmacology
- (2000) Med Lett Drugs Ther 42(1085):73-8 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
aspirin (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ASPIRIN 325 MG TABLET | Generic OTC | $0.01 each |
ASPIRIN 81 MG CHEWABLE TABLET | Generic OTC | $0.03 each |
ASPIRIN EC 325 MG TABLET | Generic OTC | $0.02 each |
ASPIRIN EC 81 MG TABLET | Generic OTC | $0.02 each |
ASPIRIN REGIMEN 81 MG EC TAB | Generic OTC | $0.02 each |
ASPIRIN-DIPYRIDAM ER 25-200 MG | Generic | $0.76 each |
asa (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ASA-BUTALB-CAFF-COD #3 CAPSULE | Generic | $1.23 each |